{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:03:24Z","timestamp":1788289404588,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Community-acquired pneumonia continues to be one of the most common causes of morbidity and mortality due to infectious disease. The aetiologies, clinical presentations, diagnostic modalities and therapeutic options are changing and outpacing the creation of management guidelines. This educational article summarizes a roundtable activity sponsored by an unrestricted educational grant by Paratek that included US experts discussing these changes and identifying gaps in the current guidelines.<\/jats:p>","DOI":"10.1093\/jac\/dkae050","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T03:01:00Z","timestamp":1714618860000},"page":"959-961","source":"Crossref","is-referenced-by-count":6,"title":["Community-acquired pneumonia: a US perspective on the guideline gap"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5720-9994","authenticated-orcid":false,"given":"Maricar","family":"Malinis","sequence":"first","affiliation":[{"name":"Yale School of Medicine, Yale University , New Haven, CT , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Abbo","sequence":"additional","affiliation":[{"name":"Miller School of Medicine, University of Miami , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Vazquez","sequence":"additional","affiliation":[{"name":"Medical College of Georgia, Augusta University , Augusta, GA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-7589","authenticated-orcid":false,"given":"Luis","family":"Ostrosky-Zeichner","sequence":"additional","affiliation":[{"name":"McGovern Medical School, University of Texas Health Science Center at Houston , Houston, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2024050203005395000_dkae050-B1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community acquired pneumonia","volume":"398","author":"Alibert","year":"2021","journal-title":"Lancet"},{"key":"2024050203005395000_dkae050-B2","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024050203005395000_dkae050-B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/03007995.2019.1675149","article-title":"The annual economic burden among patients hospitalized for community-acquired pneumonia (CAP): a retrospective US cohort study","volume":"36","author":"Divino","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2024050203005395000_dkae050-B4","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024050203005395000_dkae050-B5","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s00134-016-4394-4","article-title":"Community acquired pneumonia related to intracellular pathogens","volume":"42","author":"Cilloniz","year":"2016","journal-title":"Intensive Care Med"},{"key":"2024050203005395000_dkae050-B6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk factors for community-acquired pneumonia in adults in Europe: a literature review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"2024050203005395000_dkae050-B7","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-\u03b1 therapy","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2024050203005395000_dkae050-B8","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","article-title":"Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis","volume":"132","author":"Bercusson","year":"2018","journal-title":"Blood"},{"key":"2024050203005395000_dkae050-B9","doi-asserted-by":"crossref","first-page":"ofad166","DOI":"10.1093\/ofid\/ofad166","article-title":"Respiratory viral infections in recipients of cellular therapies: a review of incidence, outcomes, treatment, and prevention","volume":"10","author":"Dib","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2024050203005395000_dkae050-B10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2024050203005395000_dkae050-B11","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"key":"2024050203005395000_dkae050-B12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/cir274","article-title":"Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study","volume":"15","author":"Chalmers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2024050203005395000_dkae050-B13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/cit734","article-title":"Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis","volume":"58","author":"Chalmers","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024050203005395000_dkae050-B14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cid\/cit738","article-title":"Healthcare-associated pneumonia: where do we go next?","volume":"58","author":"Restrepo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024050203005395000_dkae050-B15","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1183\/09031936.00141110","article-title":"Guideline-concordant therapy and outcomes in healthcare-associated pneumonia","volume":"38","author":"Attridge","year":"2011","journal-title":"Eur Respir J"},{"key":"2024050203005395000_dkae050-B16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe community-acquired pneumonia","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"2024050203005395000_dkae050-B17","doi-asserted-by":"crossref","first-page":"107663","DOI":"10.1016\/j.pharmthera.2020.107663","article-title":"Updates on community acquired pneumonia management in the ICU","volume":"217","author":"Nair","year":"2021","journal-title":"Pharmacol Ther"},{"key":"2024050203005395000_dkae050-B18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s15010-021-01709-3","article-title":"Antibiotics in the pipeline: a literature review (2017\u20132020)","volume":"50","author":"Al-Tawfiq","year":"2022","journal-title":"Infection"},{"key":"2024050203005395000_dkae050-B19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/959\/57368104\/dkae050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/5\/959\/57368104\/dkae050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T03:01:15Z","timestamp":1714618875000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/5\/959\/7660892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae050","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2024,5]]}}}